Related Experiment Video

Updated: May 6, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.4K

Therapeutic targeting of platelet-derived growth factor receptors in solid tumors

Monika Ehnman1, Arne Östman

  • 1Karolinska Institutet, Department of Oncology-Pathology , SE-17177 Stockholm , Sweden.

Expert Opinion on Investigational Drugs
|November 12, 2013
PubMed
Abstract

Insights

Platelet-derived growth factor receptor (PDGFR) signaling is implicated in various cancers. Inhibiting PDGFR shows promise for novel cancer therapies, but understanding resistance mechanisms is key for advancing treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Platelet-derived growth factor receptor (PDGFR) aberrations are prevalent in glioblastomas, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.
  • PDGFRs expressed by tumor stroma cells may promote tumor growth and hinder drug delivery.
  • Genetic mutations affecting PDGFR signaling are also observed in other common cancer types.

Purpose of the Study:

  • To review the current understanding of PDGFR signaling in solid tumors.
  • To discuss emerging therapeutic strategies targeting PDGFR.
  • To highlight the role of PDGFR in cancer development and progression.

Main Methods:

  • Literature review of experimental studies and clinical findings on PDGFR signaling in solid tumors.
  • Analysis of ongoing research in PDGFR inhibition therapies.
  • Discussion of tyrosine kinase inhibitors and monoclonal antibodies targeting PDGFR.

Main Results:

  • PDGFR signaling plays a significant role in the pathogenesis of several solid tumors.
  • Targeting PDGFR with inhibitors is a developing therapeutic approach.
  • Stromal PDGFRs can influence tumor progression and drug penetration.

Conclusions:

  • Further research into response and resistance mechanisms is crucial for PDGFR-directed cancer therapy.
  • Clinical studies incorporating systematic analyses of PDGFR status in both malignant and stromal cells are needed.
  • Development of selective PDGFR inhibitors and companion diagnostics will facilitate therapeutic advances.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
694
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K